Bristol-myers Squibb Compnay

Universitéde Montreal

Jacques Banville

Roger Remillard

Serge Plamondon

Michael A Walker

B Narasimhulu Naidu

R Michael Lawrence

Edward H Ruediger

Shoshana L Posy

Yasutsugu Ueda

Michael Matthew Miller

John D Matiskella

Marc Gagnon

Pancras C Wong

Julia Guy

Daniel H Deon

Eldon Scott Priestley

Francis Beaulieu

Carl Ouellet

Brad D Maxwell

Alain Martel

Margaret E Sorenson

Yonghua Gai

Neelakantan Balasubramanian

Timothy P Connolly

Laurence Dube

Mark R Krystal

Graham Johnson

Annapurna Pendri

Alejandro A Aruffo

Fred Christopher Zusi

James R Burke

Michael Dore

Gilles Bouthillier

Joanne Tan

Roger Rémillard

Laurence Dubé

Yannick Rose

Doris Schuetz

Pierre Louis Beaulieu

Katharine A Grant-Young

Anne Marinier

Jean-Francois Lavallee

Dietmar A Seiffert

Sasmita Tripathy

Stephan Roy

Chen Li

Donald Thomas Corson

Hatice Belgin Gulgeze

Michael R Lawrence

Francois Tremblay

Eric Beaulieu

Mukund Ghavre

François Tremblay

Hugo Lavoie

Ting T Yin

Jean-François Lavallée

Zhuping Ma

Emeline Benoit

Laurence DubÉ

Dietmar Alfred Seiffert

Compounds, compositions and their use in the treatment of a proliferative disease or condition such as a said proliferative disease or disorder is associated with a RAF gene mutation and/or a RAS gene mutation. The compounds disclosed are of Formula I or a pharmaceutically acceptable salt or solvate thereof, wherein R, R, R, X, X, Xand Xare as defined herein.

Pyrido[3,2-d]pyrimidine compounds uses thereof for treating a proliferative disease

The present invention provides thiazole compounds of Formula I wherein W, Y, R, R, R, R, R, R, X, X, Xand Xare as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug ester or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments for treating or preventing thromboembolic disorders.

Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor 4 (PAR4) inhibitors for treating platelet aggregation

Compounds, compositions and their use in the treatment of a proliferative disease or condition such as a said proliferative disease or disorder is associated with a RAF gene mutation and/or a RAS gene mutation. The compounds disclosed are of Formula I or a pharmaceutically acceptable salt or solvate thereof, wherein R, R, R, X, X, Xand Xare as defined herein:

Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor4 (PAR4) inhibitors for treating platelet aggregation

The present invention provides thiazole compounds of Formula I wherein W, Y, R, R, R, R, R, R, X, X, Xand Xare as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug ester or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments for treating or preventing thromboembolic disorders. 

The present invention provides imidazopyridazine compounds or imidazothiadiazole compounds of Formula I having the structure: (I) wherein X, X, X, X, X, Y, W, R, R, R, R, Rand (II) are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug ester or solvate form thereof. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments for treating or preventing thromboembolic disorders. 

Imidazopyridazine and imidazothiadiazole compounds

The present invention provides imidazothiadiazole compounds of Formula (I) wherein A, B, D, R, R, R, R, X, Xand s are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments. 

Imidazothiadiazole derivatives as protease activated receptor 4 (PAR4) inhibitors for treating platelet aggregation

The invention encompasses a series bicyclic pyrimidinone compounds of Formula I which inhibit HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses pharmaceutical compositions and methods for treating those infected with HIV. 

HIV integrase inhibitors

The invention encompasses a series of bicyclic pyrimidinone compounds of Formula I which inhibit HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses pharmaceutical compositions and methods for treating those infected with HIV.

N-[[4-fluoro-2-(5-methy-1H-1,2,4-triazol-1-yl)phenyl]methyl]-4-,6,7,9-tetrahydro-3-hydroxy-9,9-dimethyl-4-oxo-pyrimido[2,1-c][1,4]oxazine-2-carboxamide as an HIV integrase inhibitor

The invention encompasses a series of bicyclic heterocyclic compounds of Formula I which are inhibitors of HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses pharmaceutical compositions and methods for treating those infected with HIV. 

Substituted imidazo[1,2-a]pyrimidines as HIV viral DNA integrase inhibitors

The invention encompasses a series cyclic bicyclic heterocyclic compounds of Formula I which are inhibitors of HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses pharmaceutical compositions and methods for treating those infected with HIV 

Bicyclic heterocycles as HIV integrase inhibitors

The invention encompasses a series cyclic bicyclic pyrimidinone compounds of Formula I which inhibit HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses pharmaceutical compositions and methods for treating those infected with HIV. 

Growing community of inventors

St-Hubert, Canada

Jacques Banville